France seeks job guarantees from Sanofi over Doliprane painkiller production
Adds quotes, details, background throughout
PARIS, Oct 14 (Reuters) -The French government needs guarantees from drugmaker Sanofi SASY.PA that production of its popular Doliprane painkiller will stay in France to allow the sale of its consumer health branch to go ahead, Economy Minister Antoine Armand said on Monday.
Sanofi said on Friday it had entered talks to sell a controlling 50% stake in its Opella business - whose brands include Doliprane - to U.S. private equity firm Clayton Dubilier & Rice, but unions fear job cuts due to this.
Doliprane, an over-the-counter painkiller, is France's best-selling drug and news that it could be partially sold to a foreign investor has prompted political concerns, in a first test case for the new government on industrial policy.
Lawmakers from across the political spectrum railed against the potential sale, and some from President Emmanuel Macron's party demanded stronger guarantees that French interests would be protected.
"If the sales goes ahead - I want to be extremely clear, we will demand extremely precise, strong and tangible conditions," Armand told journalists during a visit to a Doliprane production site in Normandy, western France.
"They must be respected and we will ensure they are respected using all the legislative and regulatory tools at our disposal," Armand added.
Junior industry minister Marc Ferraci said the conditions covered job and production volume guarantees as well as commitments to maintain research and development in France and keep using French suppliers.
Armand said the government could block the deal if its conditions were not met and said it was even possible for the state to take a shareholding to protect France's interests.
Finance Ministry sources said that discussions underway included the options of the BPI state investment vehicle taking a stake or holding a golden share, granting the state special powers over other shareholders.
Reporting by Leigh Thomas, Additional reporting by Tassilo Hummel;
Editing by Sudip Kar-Gupta and Bernadette Baum
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
